阿片类物质使用障碍
Opioid Use Disorders.
作者信息
Sharma Bikash, Bruner Ann, Barnett Gabrielle, Fishman Marc
机构信息
Mountain Manor Treatment Center, Baltimore, MD, USA.
Mountain Manor Treatment Center, Baltimore, MD, USA; Department of Pediatrics, Johns Hopkins University, Baltimore, MD, USA.
出版信息
Child Adolesc Psychiatr Clin N Am. 2016 Jul;25(3):473-87. doi: 10.1016/j.chc.2016.03.002. Epub 2016 Apr 9.
Abstract
Opioid use and addiction in adolescents and young adults is a health problem of epidemic proportions, with devastating consequences for youth and their families. Opioid overdose is a life-threatening emergency that should be treated with naloxone, and respiratory support if necessary. Overdose should always be an opportunity to initiate addiction treatment. Detoxification is often a necessary, but never sufficient, component of treatment for OUDs. Treatment for OUDs is effective but treatment capacity is alarmingly limited and under-developed. Emerging consensus supports the incorporation of relapse prevention medications such as buprenorphine and extended release naltrexone into comprehensive psychosocial treatment including counseling and family involvement.
摘要
青少年和青年中的阿片类药物使用及成瘾是一个具有流行程度的健康问题，给青少年及其家庭带来了毁灭性后果。阿片类药物过量是一种危及生命的紧急情况，应使用纳洛酮进行治疗，必要时给予呼吸支持。过量用药始终应成为启动成瘾治疗的契机。脱毒往往是阿片类药物使用障碍治疗的一个必要但绝不充分的组成部分。阿片类药物使用障碍的治疗是有效的，但治疗能力却极其有限且发展不足。新出现的共识支持将丁丙诺啡和长效纳曲酮等预防复发药物纳入包括咨询和家庭参与在内的综合心理社会治疗中。
相似文献
1
Opioid Use Disorders.阿片类物质使用障碍
Child Adolesc Psychiatr Clin N Am. 2016 Jul;25(3):473-87. doi: 10.1016/j.chc.2016.03.002. Epub 2016 Apr 9.
2
Characteristics and Receipt of Medication Treatment Among Young Adults Who Experience a Nonfatal Opioid-Related Overdose.年轻人经历非致命阿片类药物相关过量用药的特征和用药治疗情况。
Ann Emerg Med. 2020 Jan;75(1):29-38. doi: 10.1016/j.annemergmed.2019.07.030. Epub 2019 Oct 4.
3
Trends in pharmacy-based dispensing of buprenorphine, extended-release naltrexone, and naloxone during the COVID-19 pandemic by age and sex - United States, March 2019 - December 2020.在 COVID-19 大流行期间按年龄和性别划分的基于药房的丁丙诺啡、纳曲酮和纳洛酮配药趋势 - 美国，2019 年 3 月至 2020 年 12 月。
Drug Alcohol Depend. 2022 Mar 1;232:109192. doi: 10.1016/j.drugalcdep.2021.109192. Epub 2021 Nov 26.
4
Prevention of Opioid Overdose.预防阿片类药物过量。
N Engl J Med. 2019 Jun 6;380(23):2246-2255. doi: 10.1056/NEJMra1807054.
5
Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic.在 COVID-19 大流行期间，洛杉矶高过量地区的药店中丁丙诺啡和纳洛酮的获取情况。
Harm Reduct J. 2022 Jun 29;19(1):69. doi: 10.1186/s12954-022-00651-3.
6
Post-Overdose Extended-Release Buprenorphine Initiation Facilitated by a Partnership Between Emergency Medical Services and an Outpatient Substance Use Disorder Observation Unit.急诊医疗服务与门诊药物使用障碍观察单位合作，促进阿片类药物过量后长效丁丙诺啡的起始治疗。
Subst Use Addctn J. 2024 Oct;45(4):771-776. doi: 10.1177/29767342241249386. Epub 2024 May 12.
7
Assessing perceptions about medications for opioid use disorder and Naloxone on Twitter.评估关于阿片类药物使用障碍和纳洛酮药物在 Twitter 上的认知。
J Addict Dis. 2021 Jan-Mar;39(1):37-45. doi: 10.1080/10550887.2020.1811456. Epub 2020 Aug 24.
8
Current Best Practices for Acute and Chronic Management of Patients with Opioid Use Disorder.阿片类物质使用障碍患者急慢性管理的当前最佳实践
Med Clin North Am. 2022 Jan;106(1):61-80. doi: 10.1016/j.mcna.2021.08.009.
9
American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use.美国成瘾医学协会（ASAM）关于使用药物治疗阿片类药物使用成瘾的国家实践指南。
J Addict Med. 2015 Sep-Oct;9(5):358-67. doi: 10.1097/ADM.0000000000000166.
10
Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population.在美国商业保险人群中，接受阿片类药物使用障碍治疗的个体中，可注射纳曲酮、口服纳曲酮和丁丙诺啡的使用和停药情况。
J Subst Abuse Treat. 2018 Feb;85:90-96. doi: 10.1016/j.jsat.2017.07.001. Epub 2017 Jul 3.
引用本文的文献
1
Implementation of screening and assessment tools for diagnosing opioid use disorder: A systematic review.用于诊断阿片类物质使用障碍的筛查和评估工具的实施：一项系统评价
Drug Alcohol Depend Rep. 2025 Aug 20;16:100375. doi: 10.1016/j.dadr.2025.100375. eCollection 2025 Sep.
2
Perspectives from Systems-Level Key Informants on Optimizing Opioid Use Disorder Treatment for Adolescents and Young Adults.系统层面关键信息提供者对优化青少年和青年阿片类物质使用障碍治疗的看法
Children (Basel). 2025 Jul 2;12(7):876. doi: 10.3390/children12070876.
3
The Relevance of Pharmacokinetic Biomarkers in Response to Methadone Treatment: A Systematic Review.药代动力学生物标志物在美沙酮治疗反应中的相关性：一项系统评价
Pharmaceuticals (Basel). 2025 Apr 25;18(5):623. doi: 10.3390/ph18050623.
4
Opioid Use Disorders: Prevention, Diagnosis, and Treatment Strategies to Mitigate Addiction Risks.阿片类物质使用障碍：降低成瘾风险的预防、诊断及治疗策略
Curr Drug Saf. 2025;20(4):450-462. doi: 10.2174/0115748863357891250213094516.
5
An Indigenous-led buprenorphine-naloxone treatment program to address opioid use in remote Northern Canada.一项由原住民主导的丁丙诺啡-纳洛酮治疗项目，旨在解决加拿大北部偏远地区的阿片类药物使用问题。
Dialogues Health. 2024 Sep 1;5:100190. doi: 10.1016/j.dialog.2024.100190. eCollection 2024 Dec.
6
Major Depression in Comorbidity with Substance use Disorders: Patients' Features and Clinical-Neurobiological Rationale of Antidepressant Treatments.合并物质使用障碍的重度抑郁症：患者特征及抗抑郁治疗的临床神经生物学原理
Curr Neuropharmacol. 2025;23(3):256-275. doi: 10.2174/1570159X22666240827165327.
7
Emergency department management of opioid use disorder in pediatric patients.儿科患者阿片类物质使用障碍的急诊科管理
J Am Coll Emerg Physicians Open. 2024 Aug 25;5(5):e13265. doi: 10.1002/emp2.13265. eCollection 2024 Oct.
8
Acute opioid overdose in pediatric patients.小儿患者急性阿片类药物过量
J Am Coll Emerg Physicians Open. 2024 Mar 7;5(2):e13134. doi: 10.1002/emp2.13134. eCollection 2024 Apr.
9
Association of opioid or other substance use disorders with health care use among patients with suicidal symptoms.阿片类药物或其他物质使用障碍与有自杀症状患者的医疗保健使用之间的关联。
J Subst Use Addict Treat. 2024 Jan;156:209177. doi: 10.1016/j.josat.2023.209177. Epub 2023 Oct 9.
10
MedSMA℞T Adventures in PharmaCity Game: Youth Experiences and Recommendation for Use in Opioid Safety Education.MedSMA℞T在制药城的冒险游戏：青少年体验及在阿片类药物安全教育中的使用建议
Pharmacy (Basel). 2023 Sep 10;11(5):143. doi: 10.3390/pharmacy11050143.
本文引用的文献
1
Evidence of CNIH3 involvement in opioid dependence.CNIH3参与阿片类药物依赖的证据。
Mol Psychiatry. 2016 May;21(5):608-14. doi: 10.1038/mp.2015.102. Epub 2015 Aug 4.
2
Progression to regular heroin use: examination of patterns, predictors, and consequences.向常规海洛因使用的进展：模式、预测因素及后果的研究
Addict Behav. 2015 Jun;45:287-93. doi: 10.1016/j.addbeh.2015.02.014. Epub 2015 Feb 26.
3
Drug-poisoning Deaths Involving Opioid Analgesics: United States, 1999-2011.1999 - 2011年美国涉及阿片类镇痛药的药物中毒死亡情况
NCHS Data Brief. 2014 Sep(166):1-8.
4
Emerging adult age status predicts poor buprenorphine treatment retention.新兴成年人的年龄状况预示着丁丙诺啡治疗的保留率较低。
J Subst Abuse Treat. 2014 Sep;47(3):202-12. doi: 10.1016/j.jsat.2014.04.006. Epub 2014 May 20.
5
Medication-assisted therapies--tackling the opioid-overdose epidemic.药物辅助治疗——应对阿片类药物过量流行问题
N Engl J Med. 2014 May 29;370(22):2063-6. doi: 10.1056/NEJMp1402780. Epub 2014 Apr 23.
6
The temporal relationship between drug supply indicators: an audit of international government surveillance systems.药物供应指标之间的时间关系：对国际政府监测系统的审计。
BMJ Open. 2013 Sep 30;3(9):e003077. doi: 10.1136/bmjopen-2013-003077.
7
Motives for medical misuse of prescription opioids among adolescents.青少年处方阿片类药物滥用的动机。
J Pain. 2013 Oct;14(10):1208-16. doi: 10.1016/j.jpain.2013.05.004. Epub 2013 Aug 15.
8
Patient characteristics associated with buprenorphine/naloxone treatment outcome for prescription opioid dependence: Results from a multisite study.与丁丙诺啡/纳洛酮治疗处方类阿片依赖治疗结局相关的患者特征：一项多中心研究的结果。
Drug Alcohol Depend. 2013 Jul 1;131(1-2):112-8. doi: 10.1016/j.drugalcdep.2012.12.010. Epub 2013 Jan 18.
9
Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics.阿片类药物成瘾和可卡因成瘾：潜在的分子神经生物学和遗传学。
J Clin Invest. 2012 Oct;122(10):3387-93. doi: 10.1172/JCI60390. Epub 2012 Oct 1.
10
Childhood sexual abuse and risk for initiating injection drug use: a prospective cohort study.儿童期性虐待与开始注射吸毒的风险：一项前瞻性队列研究。
Prev Med. 2012 Nov;55(5):500-4. doi: 10.1016/j.ypmed.2012.08.015. Epub 2012 Aug 28.
Zotero 插件